Abstract
INTRODUCTION White matter hyperintensities (WMH) are an important imaging marker for cerebral small vessel diseases, but their risk factors and cognitive associations have not been well-documented in populations of different ethnicities and/or from different geographical regions.
METHOD Magnetic resonance imaging data of five population-based cohorts of non-demented older individuals from Australia, Singapore, South Korea, and Sweden (N = 1,946) were examined for WMH and their associations with vascular risk factors and cognition.
RESULT Factors associated with larger whole brain WMH volumes included diabetes, hypertension, stroke, current smoking, body mass index, higher alcohol intake and insufficient physical activity. Participants with moderate or higher physical activity had less WMH than those who never exercised, but the former two groups did not differ. Hypertension and stroke had stronger associations with WMH volumes in the White, compared to Asian subsample.
DISCUSSION The current study highlighted the ethnic differences in the contributions of vascular risk factors to WMH.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding for COSMIC comes from the National Institute on Aging of the National Institutes of Health (Award number: RF1AG057531). Anstey, K.J. was funded by ARC Laureate Fellowship FL190100011. Henry Brodaty was funded by NHMRC Program Grant The Funding acknowledgement for Wave 2 PATH cohort and MRI studies are NHMRC GNTs 179805, 157125. Funding for the H70-study: The study was financed by grants from the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (ALF965812, ALF 716681, ALF 72660), the Swedish Research Council (11267, 2005-8460, 2007-7462, 2012-5041, 2015-02830, 2019-01096), the Swedish Research Council RAM (2013-8717), the Swedish Research Council (NEAR 2017-00639), the Swedish Research Council for Health, Working Life and Wellfare (2012-1138, 2013-1202, 2018-00471, AGECAP 2013-2300, no 2013-2496), Hjarnfonden/Swedish Brain Foundation (FO2014-0207, FO2016-0214, FO2018-0214, FO2019-0163, FO2020-0235), Alzheimerfonden (AF-554461, AF-647651, AF-743701, AF-844671, AF-930868, AF940139, AF-968441, AF-967865), the Alzheimer Association Zenith Award (ZEN-01-3151), and Stiftelsen Handlanden Hjalmar Svenssons forskningsfond [HJSV20190229, HJSV2021039, HJSV2022059]. Funding for SLAS: Agency for Science Technology and Research (A*STAR) Biomedical Research Council (BMRC/08/1/21/19/567) and the National Medical Research Council (NMRC/1108/2007, NMRC/CIRG/1409/2014) Funding for KLOSCAD: A grant from the Korean Health Technology R&D Project, Ministry of Health and Welfare, South Korea (grant number HI09C1379 [A092077]).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethic statement The H70 study was approved by the Regional Ethical Review Board in Gothenburg (Approval Numbers: 86913, T07614, T16614, 97613, 12714, T93615, 00614, T70314, 00614, T20117, T91514, 95915, T13915), and by the Radiation Protection Committee (Approval Number: 1364). KLOSCAD (B0912089010) was approved by the Institutional Review Board of the Seoul National University Bundang Hospital. MAS Sydney was approved by the Ethics Committees of the University of New South Wales and the South Eastern Sydney and Illawarra Area Health Service. PATH study procedures were conducted in accordance with the Declaration of Helsinki and approved by the Australian National University Human Research Ethics Committee. All participants provided written informed consent. SLAS complied with the guidelines for human studies and it was conducted ethically in accordance with the Human Biomedical Research Acts (HBRA) of Singapore. All study participants gave their written informed consent and the study was approved by the National University of Singapore Institutional Review Board.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data were provided by the contributing studies to COSMIC on the understanding and proviso that the relevant study leaders be contacted for further use of their data and additional formal data sharing agreements be made. Researchers can apply to use COSMIC data by completing a COSMIC Research Proposal Form available from https://cheba.unsw.edu.au/consortia/cosmic/research-proposals.
